| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 15 | 2024 | 310 | 3.370 |
Why?
|
| Neuroendocrine Tumors | 8 | 2024 | 136 | 2.550 |
Why?
|
| Gastritis | 4 | 2025 | 39 | 2.550 |
Why?
|
| Adenocarcinoma | 16 | 2024 | 1192 | 2.440 |
Why?
|
| Pancreatic Neoplasms | 6 | 2024 | 725 | 1.460 |
Why?
|
| Biomarkers, Tumor | 10 | 2024 | 1670 | 1.210 |
Why?
|
| Gastric Mucosa | 5 | 2025 | 70 | 1.140 |
Why?
|
| Pathologists | 2 | 2025 | 40 | 1.040 |
Why?
|
| Immunohistochemistry | 10 | 2024 | 1827 | 1.000 |
Why?
|
| Collagen | 3 | 2025 | 306 | 0.980 |
Why?
|
| Ulcer | 2 | 2025 | 38 | 0.950 |
Why?
|
| Intestinal Polyposis | 1 | 2025 | 5 | 0.920 |
Why?
|
| Helicobacter Infections | 2 | 2025 | 38 | 0.900 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2025 | 45 | 0.890 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2024 | 34 | 0.880 |
Why?
|
| Intestinal Diseases | 1 | 2025 | 85 | 0.860 |
Why?
|
| Microsatellite Instability | 3 | 2024 | 64 | 0.840 |
Why?
|
| Mutation | 4 | 2025 | 4374 | 0.830 |
Why?
|
| Gastritis, Atrophic | 1 | 2023 | 4 | 0.830 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 134 | 0.800 |
Why?
|
| Intestine, Small | 1 | 2025 | 310 | 0.790 |
Why?
|
| Mutation, Missense | 1 | 2024 | 302 | 0.780 |
Why?
|
| Adenoma | 3 | 2019 | 260 | 0.770 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 382 | 0.700 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 1069 | 0.690 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 547 | 0.680 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 94 | 0.680 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 38 | 0.670 |
Why?
|
| Plasma Cells | 1 | 2021 | 88 | 0.660 |
Why?
|
| Stomach | 1 | 2021 | 115 | 0.650 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 2474 | 0.610 |
Why?
|
| Humans | 57 | 2025 | 95799 | 0.600 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2022 | 647 | 0.590 |
Why?
|
| Crohn Disease | 1 | 2025 | 809 | 0.560 |
Why?
|
| Colitis, Lymphocytic | 1 | 2018 | 4 | 0.560 |
Why?
|
| Antidiarrheals | 1 | 2018 | 14 | 0.550 |
Why?
|
| Metaplasia | 1 | 2018 | 39 | 0.550 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2017 | 4 | 0.550 |
Why?
|
| Aged | 25 | 2025 | 20848 | 0.550 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2017 | 12 | 0.540 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 540 | 0.540 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 280 | 0.530 |
Why?
|
| Female | 37 | 2025 | 49869 | 0.530 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 306 | 0.520 |
Why?
|
| Mesalamine | 1 | 2018 | 88 | 0.520 |
Why?
|
| Adult | 27 | 2025 | 28578 | 0.510 |
Why?
|
| Carcinogenesis | 1 | 2019 | 235 | 0.510 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.510 |
Why?
|
| Middle Aged | 27 | 2025 | 28206 | 0.500 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 484 | 0.500 |
Why?
|
| Biopsy | 6 | 2024 | 1208 | 0.470 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 29 | 0.460 |
Why?
|
| Esophageal Neoplasms | 4 | 2024 | 345 | 0.450 |
Why?
|
| Male | 34 | 2025 | 45685 | 0.450 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 7215 | 0.450 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 35 | 0.370 |
Why?
|
| Nevus | 1 | 2012 | 18 | 0.370 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1805 | 0.370 |
Why?
|
| Appendiceal Neoplasms | 2 | 2025 | 37 | 0.360 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 142 | 0.350 |
Why?
|
| Young Adult | 10 | 2025 | 7026 | 0.350 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 28 | 0.340 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 465 | 0.340 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 206 | 0.330 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 173 | 0.330 |
Why?
|
| Goblet Cells | 2 | 2022 | 20 | 0.320 |
Why?
|
| Leukemia, Lymphoid | 1 | 2010 | 49 | 0.320 |
Why?
|
| Inclusion Bodies | 1 | 2010 | 32 | 0.320 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2386 | 0.320 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 621 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2024 | 684 | 0.310 |
Why?
|
| Mastocytosis, Systemic | 1 | 2009 | 13 | 0.300 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 515 | 0.300 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 1087 | 0.290 |
Why?
|
| Breast Diseases | 1 | 2009 | 101 | 0.280 |
Why?
|
| Lymphocytes | 1 | 2010 | 465 | 0.270 |
Why?
|
| Melanoma | 1 | 2012 | 495 | 0.270 |
Why?
|
| Adolescent | 10 | 2021 | 9873 | 0.270 |
Why?
|
| Herpesvirus 4, Human | 2 | 2019 | 125 | 0.260 |
Why?
|
| Cysticercosis | 1 | 2007 | 2 | 0.260 |
Why?
|
| Submandibular Gland Diseases | 1 | 2007 | 9 | 0.260 |
Why?
|
| Cadherins | 2 | 2019 | 179 | 0.250 |
Why?
|
| Lip Neoplasms | 1 | 2006 | 7 | 0.250 |
Why?
|
| Salivary Glands, Minor | 1 | 2006 | 9 | 0.250 |
Why?
|
| Carcinoma | 2 | 2019 | 444 | 0.240 |
Why?
|
| Colitis, Collagenous | 1 | 2025 | 3 | 0.240 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2025 | 14 | 0.230 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2006 | 81 | 0.230 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 57 | 0.220 |
Why?
|
| Retrospective Studies | 8 | 2025 | 10273 | 0.220 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 11 | 0.220 |
Why?
|
| Intestinal Mucosa | 2 | 2022 | 825 | 0.220 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 25 | 0.220 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 61 | 0.220 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 31 | 0.210 |
Why?
|
| Adenomatous Polyps | 1 | 2024 | 15 | 0.210 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2024 | 50 | 0.210 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 127 | 0.210 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 70 | 0.210 |
Why?
|
| Exodeoxyribonucleases | 1 | 2023 | 17 | 0.210 |
Why?
|
| Peritoneal Neoplasms | 1 | 2025 | 187 | 0.200 |
Why?
|
| Biology | 1 | 2023 | 52 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 1021 | 0.200 |
Why?
|
| Opportunistic Infections | 2 | 2022 | 60 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2025 | 249 | 0.200 |
Why?
|
| Lymphocytosis | 1 | 2022 | 11 | 0.190 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.190 |
Why?
|
| Reference Standards | 1 | 2022 | 150 | 0.180 |
Why?
|
| Mitotic Index | 1 | 2022 | 22 | 0.180 |
Why?
|
| Tissue Array Analysis | 2 | 2019 | 132 | 0.180 |
Why?
|
| Aberrant Crypt Foci | 1 | 2022 | 7 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2025 | 386 | 0.180 |
Why?
|
| Gastroscopy | 1 | 2021 | 25 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 155 | 0.170 |
Why?
|
| Colitis | 1 | 2024 | 262 | 0.170 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 404 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2023 | 266 | 0.170 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 197 | 0.170 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 122 | 0.170 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 77 | 0.160 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.160 |
Why?
|
| Duodenal Neoplasms | 1 | 2019 | 21 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2019 | 36 | 0.160 |
Why?
|
| Smad4 Protein | 1 | 2019 | 26 | 0.150 |
Why?
|
| Actinomycosis | 1 | 2019 | 13 | 0.150 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2019 | 11 | 0.150 |
Why?
|
| Biomarkers | 2 | 2021 | 1931 | 0.150 |
Why?
|
| Disease Progression | 3 | 2018 | 1559 | 0.150 |
Why?
|
| Observer Variation | 1 | 2021 | 626 | 0.150 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 42 | 0.150 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 312 | 0.150 |
Why?
|
| Appendicitis | 1 | 2019 | 66 | 0.150 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 20 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 62 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2024 | 766 | 0.140 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2882 | 0.140 |
Why?
|
| Bismuth | 1 | 2018 | 8 | 0.140 |
Why?
|
| Carcinoid Tumor | 1 | 2018 | 45 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 224 | 0.140 |
Why?
|
| Salicylates | 1 | 2018 | 25 | 0.140 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 25 | 0.140 |
Why?
|
| Acinar Cells | 1 | 2017 | 8 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2021 | 3970 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 480 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 180 | 0.140 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1613 | 0.130 |
Why?
|
| Gene Amplification | 1 | 2018 | 142 | 0.130 |
Why?
|
| Cetuximab | 1 | 2018 | 119 | 0.130 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 72 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 555 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1766 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 790 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2019 | 726 | 0.130 |
Why?
|
| Lung | 2 | 2022 | 1380 | 0.130 |
Why?
|
| Microscopy, Electron | 1 | 2017 | 488 | 0.130 |
Why?
|
| Camptothecin | 1 | 2018 | 202 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 148 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2018 | 227 | 0.130 |
Why?
|
| Cecum | 1 | 2016 | 78 | 0.130 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 231 | 0.120 |
Why?
|
| Anemia | 1 | 2017 | 136 | 0.120 |
Why?
|
| Phenotype | 2 | 2019 | 2575 | 0.120 |
Why?
|
| Child | 4 | 2021 | 7618 | 0.120 |
Why?
|
| Stomach Diseases | 1 | 2015 | 19 | 0.120 |
Why?
|
| Polyps | 1 | 2015 | 26 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 801 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 372 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2017 | 747 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2023 | 9167 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 587 | 0.100 |
Why?
|
| Population | 1 | 2013 | 37 | 0.100 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 44 | 0.100 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2013 | 16 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 454 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2013 | 70 | 0.100 |
Why?
|
| United States | 3 | 2024 | 7764 | 0.090 |
Why?
|
| Nestin | 1 | 2012 | 18 | 0.090 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2011 | 2 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 166 | 0.090 |
Why?
|
| Genomics | 1 | 2017 | 857 | 0.090 |
Why?
|
| Age Factors | 1 | 2016 | 1957 | 0.090 |
Why?
|
| Microbiota | 1 | 2016 | 426 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2605 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2019 | 3106 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 579 | 0.080 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2010 | 4 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 449 | 0.080 |
Why?
|
| Mast Cells | 1 | 2009 | 97 | 0.070 |
Why?
|
| Leucovorin | 2 | 2020 | 215 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 85 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2010 | 415 | 0.070 |
Why?
|
| Fever | 1 | 2008 | 131 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 549 | 0.070 |
Why?
|
| Wuchereria bancrofti | 1 | 2007 | 2 | 0.070 |
Why?
|
| Filariasis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Lung Abscess | 1 | 2007 | 5 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 30 | 0.070 |
Why?
|
| Histiocytosis, Sinus | 1 | 2007 | 17 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 3155 | 0.060 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2007 | 7 | 0.060 |
Why?
|
| Mammaplasty | 1 | 2009 | 124 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 307 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 983 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.060 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2007 | 60 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2495 | 0.060 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2025 | 92 | 0.060 |
Why?
|
| Granuloma | 2 | 2019 | 65 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2025 | 136 | 0.050 |
Why?
|
| Octreotide | 1 | 2024 | 29 | 0.050 |
Why?
|
| Prognosis | 1 | 2012 | 3990 | 0.050 |
Why?
|
| Microwaves | 1 | 2023 | 32 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2777 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 370 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2024 | 137 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 13 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2023 | 178 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 42 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 98 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 131 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 89 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2024 | 304 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2022 | 85 | 0.040 |
Why?
|
| Esophagectomy | 1 | 2022 | 92 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 59 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2022 | 149 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 87 | 0.040 |
Why?
|
| India | 2 | 2013 | 138 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 2021 | 43 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 191 | 0.040 |
Why?
|
| Colon | 1 | 2024 | 542 | 0.040 |
Why?
|
| Hydrogels | 1 | 2021 | 91 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 126 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 930 | 0.040 |
Why?
|
| DNA Repair | 1 | 2022 | 376 | 0.040 |
Why?
|
| Actinomyces | 1 | 2019 | 5 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 101 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 198 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2019 | 27 | 0.040 |
Why?
|
| Duodenum | 1 | 2019 | 112 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 114 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 81 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 60 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 353 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 99 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3904 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2007 | 108 | 0.030 |
Why?
|
| Endoscopy | 1 | 2020 | 374 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 62 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1505 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 463 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1194 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 165 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1880 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 12537 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 513 | 0.030 |
Why?
|
| Endosonography | 1 | 2015 | 101 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 910 | 0.030 |
Why?
|
| Homeostasis | 1 | 2016 | 467 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 234 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 506 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 5961 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2013 | 147 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2042 | 0.020 |
Why?
|
| Axilla | 1 | 2013 | 110 | 0.020 |
Why?
|
| Animals | 3 | 2021 | 28889 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2013 | 108 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2011 | 34 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 703 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1463 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1714 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2089 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2011 | 152 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 158 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2010 | 130 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 90 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3491 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 119 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 554 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1739 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4664 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 15 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2385 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1079 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 41 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 231 | 0.020 |
Why?
|
| Chin | 1 | 2007 | 9 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 705 | 0.020 |
Why?
|